Interaction between HBsAg response and the prognosis of patients with HBV-associated HCC receiving anti-PD-1/PD-L1

Abstract Background Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors are widely used in advanced hepatocellular carcinoma (HCC). Hepatitis B virus (HBV) is a major etiology of HCC, yet predictive biomarkers for anti-PD-1/PD-L1 efficacy in HBV-related HCC (HBV-HCC) remain sc...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Xia Zhang, Qing Xu, Qin-Xia Ma, Yong-Lin Yang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-12-01
Colecção:	BMC Infectious Diseases
Assuntos:	PD-1/PD-L1 inhibitors HBsAg HBV-HCC
Acesso em linha:	https://doi.org/10.1186/s12879-025-12312-4
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!